mRNA vaccines are safe during pregnancy, says Lancet report

Manish Sadarangani and colleagues in The Lancet Infectious Disease report findings from the Canadian National Vaccine Safety (Canvas) Network, assessing adverse events over the coming week. mRNA COVID-19 Vaccination Comparison between pregnant people and with both non-vaccinated pregnant people and vaccinated non-pregnant women.

“In this large prospective study, the authors found that 226 (4 0%) of 5597 vaccinated pregnant people reported a significant health event (absence of work or school, medical consultation, or new or worsening enough to prevent daily activities). health event) after dose 1 of primary chain mRNA COVID-19 (mRNA-1273.) [Moderna] or bnt162b2 [Pfizer BioNTech]) vaccination, with similar adverse events for both vaccines. Additionally, 227 (7 3%) of 3108 vaccinated pregnant people reported a significant health event after dose 2 of the primary series, and this varied by vaccine type, 147 out of 1216 (12 3%) ) reported a significant health event after 2 doses of mRNA-1273 and 80 (4 2 %) of 1892 after dose 2 of BNT162b2, according to the report.

The most common significant health events following both doses in pregnant people were malaise or myalgia (66. [3·5%] BNT162b2 in 1892 and 139 . for two doses of [11·4%] 1216 for two doses of mRNA-1273) and headache or migraine (41 [2·1%] In 1892 for two doses of BNT162b2 and 103 [8·5%] 1216 for two doses of mRNA-1273). Serious health events, defined as any event resulting from emergency department visits or hospital admissions in the previous 7 days, were rare (<1·0% in all groups).

The most frequently reported adverse pregnancy outcome was a combined result of miscarriage and stillbirth and was reported at a similar frequency in vaccination (81 [1·4%] 5597) and unvaccinated (seven.) [2·1%] out of 339) pregnant people. In a multivariable analysis among those vaccinated with mRNA-1273 or BNT162b2, pregnancy was associated with lower odds of significant adverse events reported in the week following receipt of each dose (any mRNA dose 1: aOR 0 63 [95% CI 0·55–0·72], Any mRNA dose 2: aOR 0 62 [0·54–0·71]) Additionally, pregnancy was not associated with an increased risk of serious adverse events following vaccination after dose 1 of BNT162B2 or mRNA-1273, but was associated with an increased risk after dose 2 of mRNA-1273 (AOR 2 3 [95% CI 1·2–4·2]) Of the 1216 pregnant women who received the mRNA-1273 dose 2 , 11 (0 9%) reported a serious adverse event within 7 days.

In addition to being safe in pregnancy, other studies have shown that mRNA COVID-19 vaccines can reduce the risk of serious illness in pregnant people and the risk of COVID-19 hospitalization in infants younger than 6 months of age. are effective in Safety is especially important in babies born to those vaccinated during pregnancy because the mRNA COVID-19 vaccine was approved by the FDA on June 17, 2022, and by the CDC on June 18, 2022 from 6 months to 5 Was recommended for children of one year of age. ,9 There is currently no vaccine available for infants under six months of age.

first article